Dapagliflozin in heart failure: new frontiers

Jasper Tromp*, Sean P. Collins

*Corresponding author for this work

    Research output: Contribution to journalEditorialAcademicpeer-review

    3 Citations (Scopus)
    25 Downloads (Pure)


    This article refers to 'The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics', by J.J.V. McMurray et al., published in this issue on pages 1402-1411.

    Original languageEnglish
    Pages (from-to)1412-1414
    Number of pages3
    JournalEuropean Journal of Heart Failure
    Issue number11
    Publication statusPublished - Nov-2019

    Cite this